Recruiting

A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(9 sites)

United States

Memorial Sloan Kettering Cancer Center, New York, New York

University of Texas MD Anderson Cancer Center, Houston, Texas

Fred Hutchinson Cancer Center, Seattle, Washington

United Kingdom

The Beatson West of Scotland Cancer Centre, NHS Greater Glasgow & Clyde, Glasgow

St James's University Hospital, The Leeds Teaching Hospitals NHS Trust, Leeds

The Royal Marsden, NHS Foundation Trust, London

The Christie NHS Foundation Trust, Manchester

The Freeman Hospital, Newcastle-upon-Tyne NHS Foundation Trust, Newcastle upon Tyne

Weston Park Cancer Centre, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield